Objetivo Two different aspects of immunity to human plasmodium vivax malaria will be explored. (1) Anti-disease immunity and (2) Transmission blocking immunity. 1) In residents of malaria endemic regions, repeated infections lead to a decrease in the severity of disease. This clinical immunity is distinct from, and appears before immunity directed against the parasite itself. The proposers have demonstrated that clinical paroxysms in P.vivax malaria i.e. periodic episodes of fever with chills and rigors, are accompanied by a transient but massive rise in serum TNF levels. Further, during paroxysms, TNF acting in conjunction with other as yet unidentified complementary serum factor(s) mediate killing of intraerythrocytic malaria parasites. Both serum TNF levels and other parasite killing factor(s) are significantly reduced in clinically immune subjects, suggesting that they are associated with clinical disease. There is evidence that clinical immunity is achieved by maintaining these cytokines at a low level; this is by the acquisition of antibodies which neutralize parasite antigens that induce the production of these cytokines. It is the purpose of this proposal to study disease and clinical immunity to P.vivax in humans With the objectives of identifying parasite antigens that induce cytokines associated with disease. This could form the basis of an "anti-disease" vaccine against malaria. 2) Another approach to vaccination against malaria is to immunize against the sexual stages which mediate transmission of the parasite from man to mosquito. Using monoclonal antibodies, we have identified several targets of such "transmission blocking immunity" in P.vivax. Epitopes involved in this immunity are dependent on tertiary conformational structure which cannot be reproduced in recombinant polypeptides expressed in bacteria. This hinders the cloning of the corresponding genes. Here we propose to use a eukaryotic expression system, COS cells, to overcome this problem and screen for cells expressing transmission blocking vaccine candidates by "panning" with our transmission blocking immune reagents. Ámbito científico medical and health scienceshealth sciencesinfectious diseasesmalarianatural sciencesbiological sciencesmicrobiologybacteriologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological scienceszoologyinvertebrate zoology Programa(s) FP3-STD 3 - Specific research and technological development programme (EEC) in the field of the life sciences and technologies for developing countries, 1990-1994 Tema(s) Data not available Convocatoria de propuestas Data not available Régimen de financiación CSC - Cost-sharing contracts Coordinador UNIVERSITY OF EDINBURGH Aportación de la UE Sin datos Dirección King's Building, Darwing Building, Mayfield Road EH9 3Jr EDINBURGH Reino Unido Ver en el mapa Coste total Sin datos Participantes (2) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo Institut Pasteur Francia Aportación de la UE Sin datos Dirección 25 rue du Docteur Roux 75724 Paris Ver en el mapa Coste total Sin datos University of Colombo Sri Lanka Aportación de la UE Sin datos Dirección Kynsey Road 8 Colombo Ver en el mapa Coste total Sin datos